Biological Activity:

CUDC-101 is a potent multi-target inhibitor targeting HDAC, EGFR and HER2 with IC₅₀ of 4.4 nM, 2.4 nM, and 15.7 nM, respectively. It is specific for class I and class II HDACs, not for class III Sir-type HDACs, and has > 50-fold selectivity against other protein kinases. CUDC-101 displays broad antiproliferative activity in many human cancer cell types with IC₅₀ of 0.04-0.80 μM, exhibiting a higher potency than erlotinib, lapatinib, and combinations of vorinostat with either erlotinib or lapatinib in most cases. It can inhibit EGFR and Her2 phosphorylation, reduce cell proliferation and induce apoptosis in HCC827 non-small cell lung cancer (NSCLC) xenografts.  It inhibits EGFR and induces upregulation of acetylated histone H3 in a dose-dependent fashion.  In vivo CUDC-101 promotes tumor regression in various cancer xenograft models such as non-small cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. Currently it is in Phase I clinical trials for advanced head and neck, gastric, breast, liver and non-small cell lung cancer tumors.

How to Use:

• In vitro:  CUDC-101 was used at 1 µM final concentration in vitro and in cellular assays.
• In vivo: CUDC-101 was IP or IV dosed to mice at 120 mg/kg once per day in the xenograft tumor model of Hep-G2, H358, A549, MDA-MB468, HCT116, CAL-27, HepG2, or HPAC.

Reference:

• Product Specification:
• Product MSDS:

Products are for research use only. Not for human use.